NCT07660419 Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque
| NCT ID | NCT07660419 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China National Center for Cardiovascular Diseases |
| Condition | Coronary Artery Disease (CAD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 176 participants |
| Start Date | 2024-12-31 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 176 participants in total. It began in 2024-12-31 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-center, randomized controlled trial aims to evaluate the efficacy of a mobile internet-based, home-based cardiac rehabilitation program in patients with mild to moderate coronary artery stenosis. A total of 176 eligible participants will be randomized to receive either a personalized lifestyle intervention via a mobile platform or routine clinical care. The primary endpoint is the change in non-calcified coronary plaque volume, as measured by coronary computed tomography angiography (CTA) at 12 months. Participants will be followed for a total of 36 months to comprehensively assess the long-term impact of this digital lifestyle intervention on plaque progression and cardiovascular outcomes.
Eligibility Criteria
Inclusion Criteria: * 1.Diagnosis of mild-to-moderate coronary artery stenosis: presence of plaque in any coronary artery causing mild (\<50%) or moderate (50%-69%) luminal stenosis. 2.Age between 18 and 70 years. 3.Asymptomatic during exercise or recovery phases of cardiopulmonary assessment, including absence of angina, ST-segment depression, or complex arrhythmias at rest or during exercise. 4.Normal troponin levels. 5.Provided signed informed consent. Exclusion Criteria: * 1\. Severe coronary artery stenosis. 2.Presence of severe respiratory or cardiovascular diseases (e.g., acute myocardial infarction, acute tachyarrhythmia, pulmonary edema, severe aortic stenosis). 3.Angina symptoms or signs during low-intensity exercise (\<5 METs) or recovery. 4.Complex arrhythmias at rest or during exercise. 5.Hemodynamic abnormalities during exercise (e.g., failure of systolic blood pressure or heart rate to increase, or a decrease in blood pressure with increased exercise workload). 6.Severe psychological disorders. 7.Left ventricular ejection fraction (LVEF) \< 40%. 8.Elevated troponin levels. 9.Inability to undergo cardiopulmonary exercise testing due to neuromuscular or musculoskeletal disorders. 10.Presence of other severe comorbidities. 11.Refusal to sign informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07660419 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Coronary Artery Disease (CAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07660419 currently recruiting?
Yes, NCT07660419 is actively recruiting participants. Contact the research team at 29611290@qq.com for enrollment information.
Where is the NCT07660419 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07660419 clinical trial?
NCT07660419 is sponsored by China National Center for Cardiovascular Diseases. The trial plans to enroll 176 participants.